65,437 trials
Open-Angle Glaucoma · Ocular Hypertension
Primary: Mean Diurnal IOP Change From Baseline at Month 3 — -8.5; -8.3 millimeters of mercury (mmHg)
Tobacco Use Cessation · Alcohol-related Disorders
Primary: Smoking Abstinence — 20; 1 participants — p=<.01
Contraception
Primary: Overall Satisfaction Rate at 18 Months (Last Observation Carried Forward, LOCF) — 82.1; 81.9 Percentage of participants
Lymphoma · Hodgkin Disease · Lymphoma, Non-Hodgkin
Primary: Phase I (Dose Escalation Phase): MTD and DLTs of PCI-24781 Administered Twice Daily (BID) Measure: Disease Response — 0; 3; 0; 2 participants
Allergy
Primary: Scores on a Scale (Average of Total Symptom Scores) — 7.02; 8.30; 7.87 Scores on a scale — p=<0.05
Exudative Age-related Macular Degeneration
Primary: Caliber of Choroidal New Vessel (CNV) — 43.53 micrometer
HIV
Primary: ART Initiation — 181; 63 participants
Substance Abuse Problem
Primary: Results (Unadjusted) for Criminal Activities in Past 30 Days at Baseline and Follow-up for Women in Women-Only Treatment and Mixed-Gender Treatment — 63.9; 76.9; 22.3…
Age Related Macular Degeneration
Primary: Mean Change From Baseline in Visual Acuity — 1.8; 1.0 ETDRS letters
Ileostomy - Stoma
Primary: Degree of Leakage — 1.9; 2.5; 3.1 units on a scale
Rheumatoid Arthritis
Primary: Proportion of Patients With ACR20 at Week 24, Comparison Between Fostamatinib and Placebo. — 49.0; 44.4; 34.2 Percentage of responders — p=<0.001
Retraction of Colostomy
Primary: Total Opioid Burden — 112.38; 19.8 mg morphine equivalent
Glaucoma
Primary: Mean Change in Intraocular Pressure (IOP) From Baseline (Prior Therapy) at Week 8 — -3.60 milllimeters mercury (mmHg)
Laryngismus
Primary: LMA Insertion Condition — 14; 21; 24; 7 participants
Cystic Fibrosis · Exocrine Pancreatic Insufficiency
Primary: Percent Coefficient of Fat Absorption (CFA%) — 88.28; 62.76 percent CFA — p=<0.001